Treatment of resistant Hodgkin's disease with CCNU, etoposide and prednimustine (CEP).

Abstract

Starting in January 1984, 63 patients with resistant Hodgkin's disease received CEP as salvage-usually third-line-chemotherapy. Complete response (CR) was achieved in 3%, partial response (PR) in 51%. The median duration of remission (CR + PR) was greater than 15 months. Treatment was generally well tolerated. Our results confirm that CEP is an effective therapeutic regimen in resistant Hodgkin's disease.

• Authors: I Szántó, T Fleischmann, S Eckhardt
• Journal: Oncology (Oncology) Vol. 48 Issue 6 Pg. 456-8 ( 1991) ISSN: 0030-2414 [Print] Switzerland
• PMID: 1749581 (Publication Type: Clinical Trial, Journal Article)

Chemical References

• Etoposide
• Lomustine
• Prednimustine

Topics

• Adolescent
• Adult
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Combined Modality Therapy
• Etoposide (administration & dosage)
• Hodgkin Disease (drug therapy, radiotherapy)
• Humans
• Lomustine (administration & dosage)
• Middle Aged
• Prednimustine (administration & dosage)